BiomX (PHGE) Net Income towards Common Stockholders (2018 - 2026)
BiomX (PHGE) posted Net Income towards Common Stockholders of $19.2 million for Q1 2026, up 4.96% sequentially from $18.3 million in Q4 2025, and up 151.01% YoY from $7.7 million in Q1 2025.
BiomX (PHGE) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
BiomX has reported Net Income towards Common Stockholders for 9 years, with the latest figure at $19.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 151.01% year-over-year to $19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.7 million (up 373.23% YoY) and the FY2025 annual result came in at $36.2 million, up 304.2% from the prior year.
- Net Income towards Common Stockholders rose to $19.2 million in Q1 2026 per PHGE's latest filing, from $18.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $19.2 million in Q1 2026 and troughed at -$46.8 million in Q4 2023.
- A 5-year average of -$781625.0 and a median of $2.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders tumbled 404.7% in 2023, then jumped 732.15% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at $15.4 million in 2022, then sank by 404.7% to -$46.8 million in 2023, then soared by 55.3% to -$20.9 million in 2024, then surged by 187.47% to $18.3 million in 2025, then grew by 4.96% to $19.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $19.2 million, $18.3 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | 19.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.23 Mn |
| Dec 31, 2025 | 18.32 Mn |
| Sep 30, 2025 | 9.17 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Dec 31, 2024 | -20.94 Mn |
| Sep 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -955,000.00 |
| Dec 31, 2023 | -46.85 Mn |
| Sep 30, 2023 | 7.91 Mn |
| Jun 30, 2023 | 6.41 Mn |
| Mar 31, 2023 | -6.36 Mn |
| Dec 31, 2022 | 15.38 Mn |
| Sep 30, 2022 | -6.78 Mn |
| Jun 30, 2022 | -7.48 Mn |
| Mar 31, 2022 | -8.17 Mn |
| Dec 31, 2021 | -10.46 Mn |
| Sep 30, 2021 | -10.03 Mn |
| Jun 30, 2021 | -7.34 Mn |
| Mar 31, 2021 | -8.40 Mn |